From GlobeNewswire.: 2024-04-04 16:30:00

Mersana Therapeutics announced the grant of an inducement award in the form of a restricted stock unit (RSU) to a new employee, allowing them to acquire 35,100 shares of common stock. The award will vest in installments over four years, contingent on the employee’s continued service. Mersana is focused on developing antibody-drug conjugates (ADCs) to target cancers with unmet medical needs, utilizing proprietary platforms like Dolasynthen and Immunosynthen. Their pipeline includes products like XMT-1660 and XMT-2056, both targeting specific cancer markers. For more information, investors can visit Mersana’s website.

For more information, contact Jason Fredette at 617-498-0020 or [email protected].



Read more at GlobeNewswire.: Mersana Therapeutics Announces Inducement Grants Under